SHORT DESCRIPTION
For oncology applications, this invention offers spherical nucleic acids with an enzyme-cleavable PEG layer that combines prolonged circulation with enhanced tumor cell uptake. BACKGROUND
Conventional nanomaterials struggle to balance stability during circulation with effective delivery into tumor cells. The need exists for a robust technology that overcomes these challenges without undesired immunogenicity. ABSTRACT
This invention presents a spherical nucleic acid (SNA) platform with a sheddable PEG layer attached via an enzyme-cleavable peptide linker. The design protects the nucleic acids in blood following systemic administration while allowing targeted PEG removal by tumor-overexpressed matrix metalloproteinases (MMPs). Laboratory studies confirm that these SNAs possessed prolonged blood circulation with minimal immune response and enhanced cellular uptake in tumor microenvironments relative to non-sheddable counterparts. The approach provides a promising route for targeted therapeutic delivery and gene regulation in oncology. APPLICATIONS
IP STATUS
US Patent Pending.